Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a suscep...
Saved in:
| Published in | BMC medical research methodology Vol. 10; no. 1; p. 18 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
08.03.2010
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2288 1471-2288 |
| DOI | 10.1186/1471-2288-10-18 |
Cover
| Abstract | Background
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.
Methods
We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.
Results
A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.
Conclusion
Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. |
|---|---|
| AbstractList | Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.BACKGROUNDAntibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.METHODSWe present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.RESULTSA significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.CONCLUSIONAlthough limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. Abstract Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile. |
| ArticleNumber | 18 |
| Audience | Academic |
| Author | Megas, Françoise Coudeville, Laurent Bailleux, Fabrice Riche, Benjamin Ecochard, René Andre, Philippe |
| AuthorAffiliation | 1 Sanofi pasteur, 2 avenue Pont Pasteur F-69367 Lyon cedex 07 France 2 Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558; Université Claude Bernard, Laboratoire Biostatistique Santé, Lyon, France |
| AuthorAffiliation_xml | – name: 1 Sanofi pasteur, 2 avenue Pont Pasteur F-69367 Lyon cedex 07 France – name: 2 Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558; Université Claude Bernard, Laboratoire Biostatistique Santé, Lyon, France |
| Author_xml | – sequence: 1 givenname: Laurent surname: Coudeville fullname: Coudeville, Laurent email: laurent.coudeville@sanofipasteur.com organization: Sanofi pasteur – sequence: 2 givenname: Fabrice surname: Bailleux fullname: Bailleux, Fabrice organization: Sanofi pasteur – sequence: 3 givenname: Benjamin surname: Riche fullname: Riche, Benjamin organization: Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558, Université Claude Bernard, Laboratoire Biostatistique Santé – sequence: 4 givenname: Françoise surname: Megas fullname: Megas, Françoise organization: Sanofi pasteur – sequence: 5 givenname: Philippe surname: Andre fullname: Andre, Philippe organization: Sanofi pasteur – sequence: 6 givenname: René surname: Ecochard fullname: Ecochard, René organization: Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558, Université Claude Bernard, Laboratoire Biostatistique Santé |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20210985$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUk1v1DAQjVAR_YAzNxTBgVNaO4kThwNSVfFRqRISgrM1scdZrxw7xEmr5S_xJ3F2S-lWfCiHxDPvvXjem-PkwHmHSfKcklNKeXVGy5pmec55RklG-aPk6K5ycO_7MDkOYU0IrXlRPUkOc5JT0nB2lPz4jBYm411YmSFtcbpBdOkKsIeus_Nk3LabGbcyrYnHLgU3mdarTTqZacQQzyqV1jgjwabD6CeUCyWFDowLU2qctjO67_AmVXiN1g89umlLg2GwkbaFe51C2sIGgwGXjrHt-wy1jmoh7b1C-zR5rMEGfHb7Pkm-vn_35eJjdvXpw-XF-VUmK9ZMGdXAFaiqJXUNRDFoWcuo1BK5lgohV0XbMEa1LPKSKIqsLCWTGhpaFjkvi5PkcqerPKzFMJoexo3wYMS24MdOwDgZaVHkDYJkNS-pzkuQLaesQFXWpZayUpRHLbLTmt0Amxuw9k6QErFkKJaUxJLStrJQ3u4ow9z2qGQ0awS7d4_9jjMr0flrkXNGa5JHgde3AqP_NmOYRG-CRGvBoZ-DqIuCV5xULCJfPkCu_Ty6aK5oKONVQwmNoFc7UAdx4pimj3-Vi6Q4z_OiJJQ1y61P_4CKj8LeyLi12sT6HuHF_THv5vu1mxHAdgA5-hBG1EKaabsrUdnYf_h39oD3f8dvQwoR6Tocf9vwN8pP9owZvg |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2015_10_131 crossref_primary_10_1016_j_regg_2018_06_004 crossref_primary_10_4161_hv_6_10_12636 crossref_primary_10_1016_j_vaccine_2018_08_040 crossref_primary_10_1080_23744235_2017_1361547 crossref_primary_10_1093_infdis_jiz004 crossref_primary_10_1111_irv_12706 crossref_primary_10_1371_journal_pbio_3002864 crossref_primary_10_1016_j_vaccine_2016_05_067 crossref_primary_10_1038_s41598_017_05579_4 crossref_primary_10_1016_j_jpeds_2017_08_071 crossref_primary_10_1093_infdis_jiae258 crossref_primary_10_1128_JVI_00285_16 crossref_primary_10_1016_j_cmi_2018_05_002 crossref_primary_10_1016_j_tmaid_2020_101872 crossref_primary_10_1016_j_vaccine_2012_05_060 crossref_primary_10_1016_j_vaccine_2015_11_058 crossref_primary_10_1038_s41467_019_09652_6 crossref_primary_10_1371_journal_pone_0056023 crossref_primary_10_1016_j_vaccine_2017_06_038 crossref_primary_10_1128_CVI_00604_15 crossref_primary_10_1371_journal_pone_0036773 crossref_primary_10_1016_j_cmi_2020_07_033 crossref_primary_10_1097_MD_0000000000038809 crossref_primary_10_1136_bmj_2023_077076 crossref_primary_10_1080_1744666X_2017_1389647 crossref_primary_10_1111_j_1750_2659_2011_00242_x crossref_primary_10_1093_infdis_jiv332 crossref_primary_10_1093_infdis_jix632 crossref_primary_10_1111_irv_12935 crossref_primary_10_1016_j_vaccine_2015_09_016 crossref_primary_10_1080_21645515_2015_1011987 crossref_primary_10_1016_j_vaccine_2018_07_004 crossref_primary_10_1016_S1473_3099_19_30584_5 crossref_primary_10_1016_j_jinf_2014_09_003 crossref_primary_10_1038_s41467_021_21954_2 crossref_primary_10_1111_irv_12702 crossref_primary_10_1016_j_vaccine_2014_08_031 crossref_primary_10_1097_CM9_0000000000002001 crossref_primary_10_1111_irv_70014 crossref_primary_10_1038_gene_2016_34 crossref_primary_10_1038_ijo_2017_131 crossref_primary_10_1128_JVI_02289_14 crossref_primary_10_1371_journal_pone_0306953 crossref_primary_10_3390_vaccines10050804 crossref_primary_10_1111_irv_12805 crossref_primary_10_1093_infdis_jiw311 crossref_primary_10_3389_fimmu_2022_1081107 crossref_primary_10_1016_j_vaccine_2011_05_001 crossref_primary_10_1016_S1473_3099_11_70156_6 crossref_primary_10_1093_ofid_ofab477 crossref_primary_10_1016_j_coviro_2016_12_004 crossref_primary_10_1080_21645515_2022_2132798 crossref_primary_10_1186_s12951_025_03122_6 crossref_primary_10_1099_vir_0_067488_0 crossref_primary_10_1371_journal_pone_0056700 crossref_primary_10_12688_f1000research_75869_2 crossref_primary_10_3389_fimmu_2023_1143451 crossref_primary_10_1016_j_virol_2015_08_004 crossref_primary_10_1016_j_vaccine_2019_10_046 crossref_primary_10_1002_jmv_29858 crossref_primary_10_1093_jpids_piy057 crossref_primary_10_3389_fimmu_2023_1253626 crossref_primary_10_1016_j_vaccine_2016_01_042 crossref_primary_10_3390_v12090968 crossref_primary_10_1016_j_ijid_2020_06_043 crossref_primary_10_1093_infdis_jiae122 crossref_primary_10_1186_s12879_018_3444_7 crossref_primary_10_1371_journal_pone_0047448 crossref_primary_10_1002_jmv_29743 crossref_primary_10_1371_journal_ppat_1004310 crossref_primary_10_3390_vaccines12091079 crossref_primary_10_12688_f1000research_75869_1 crossref_primary_10_1016_j_msard_2025_106382 crossref_primary_10_1038_s41541_022_00463_3 crossref_primary_10_1017_S0950268816002156 crossref_primary_10_1016_j_vaccine_2023_11_038 crossref_primary_10_1093_infdis_jiae615 crossref_primary_10_1016_j_cell_2023_09_022 crossref_primary_10_1016_j_provac_2014_07_004 crossref_primary_10_1093_ofid_ofae559 crossref_primary_10_1016_j_ijid_2012_05_1025 crossref_primary_10_12938_bmfh_2022_037 crossref_primary_10_1021_jacsau_3c00695 crossref_primary_10_1126_scitranslmed_3008409 crossref_primary_10_1016_j_vaccine_2016_11_013 crossref_primary_10_1016_j_jviromet_2013_03_001 crossref_primary_10_1007_s40506_024_00270_5 crossref_primary_10_1080_21645515_2019_1565269 crossref_primary_10_1038_s41467_021_25713_1 crossref_primary_10_3390_vaccines13030304 crossref_primary_10_4155_bio_11_327 crossref_primary_10_4161_hv_22908 crossref_primary_10_1017_S0950268814000855 crossref_primary_10_3390_vaccines3020373 crossref_primary_10_1128_CVI_00475_15 crossref_primary_10_1097_EDE_0b013e3182302e8e crossref_primary_10_3390_vaccines10060888 crossref_primary_10_1111_sji_12801 crossref_primary_10_3390_vaccines10111924 crossref_primary_10_1016_j_vaccine_2011_07_050 crossref_primary_10_3390_vaccines8020325 crossref_primary_10_3390_v16030479 crossref_primary_10_1016_j_vaccine_2022_03_065 crossref_primary_10_3389_fimmu_2019_00611 crossref_primary_10_1016_j_stem_2025_01_014 crossref_primary_10_1016_j_vaccine_2014_08_068 crossref_primary_10_1186_1471_2288_13_29 crossref_primary_10_3390_vaccines12030303 crossref_primary_10_1016_j_vaccine_2015_10_119 crossref_primary_10_1016_j_vaccine_2010_08_102 crossref_primary_10_1016_j_epidem_2015_06_001 crossref_primary_10_1016_j_mehy_2023_111135 crossref_primary_10_3390_v14091937 crossref_primary_10_1016_j_jinf_2019_11_024 crossref_primary_10_1111_j_1750_2659_2011_00229_x crossref_primary_10_1016_S1473_3099_10_70296_6 crossref_primary_10_1371_journal_pone_0140702 crossref_primary_10_1038_s41541_024_00891_3 crossref_primary_10_1016_j_vaccine_2019_08_071 crossref_primary_10_1186_s12874_015_0096_9 crossref_primary_10_1038_s41541_024_00937_6 crossref_primary_10_1155_2018_7251793 crossref_primary_10_3390_vaccines6030039 crossref_primary_10_1080_21645515_2017_1338547 crossref_primary_10_1038_s41591_021_01377_8 crossref_primary_10_1371_journal_pone_0015559 crossref_primary_10_1093_cid_cit048 crossref_primary_10_1093_infdis_jiu186 crossref_primary_10_1016_j_coi_2018_05_010 crossref_primary_10_1111_imr_12514 crossref_primary_10_1038_s41467_023_44668_z crossref_primary_10_1051_medsci_2019266 crossref_primary_10_1038_s41541_017_0012_x crossref_primary_10_1093_crocol_otaa086 crossref_primary_10_1186_s12917_015_0586_3 crossref_primary_10_1371_journal_pcbi_1006377 crossref_primary_10_1016_j_micpath_2012_11_013 crossref_primary_10_1093_ofid_ofv067 crossref_primary_10_3390_vaccines10040593 crossref_primary_10_1128_mBio_00417_16 crossref_primary_10_1371_journal_pone_0024384 crossref_primary_10_1101_cshperspect_a038653 crossref_primary_10_1186_1742_4933_11_10 crossref_primary_10_1016_j_epidem_2017_03_003 crossref_primary_10_1093_ibd_izz164 crossref_primary_10_1371_journal_pone_0028063 crossref_primary_10_1016_j_vaccine_2024_126579 crossref_primary_10_4161_hv_8_1_18214 crossref_primary_10_1089_vim_2013_0111 crossref_primary_10_1016_j_vaccine_2012_09_005 crossref_primary_10_1016_j_vaccine_2023_09_025 crossref_primary_10_3390_ijerph19159425 crossref_primary_10_1016_j_vaccine_2018_05_117 crossref_primary_10_1016_j_vaccine_2022_04_049 crossref_primary_10_1093_infdis_jiaa293 crossref_primary_10_1586_erv_13_35 crossref_primary_10_1093_nar_gkt1133 crossref_primary_10_1016_j_trim_2019_01_001 crossref_primary_10_1371_journal_pone_0246613 crossref_primary_10_1038_s41541_022_00492_y crossref_primary_10_1586_14760584_2016_1164046 crossref_primary_10_2139_ssrn_4751438 crossref_primary_10_3390_vaccines12121307 crossref_primary_10_1002_elps_202100269 crossref_primary_10_1073_pnas_1303117110 crossref_primary_10_1016_j_vaccine_2020_01_088 crossref_primary_10_1016_j_bbi_2013_10_003 crossref_primary_10_1016_j_jia_2023_11_007 crossref_primary_10_3390_vaccines9030257 crossref_primary_10_1038_s41467_022_29310_8 crossref_primary_10_3390_v14081692 crossref_primary_10_1111_ajt_15296 crossref_primary_10_1016_j_vaccine_2010_10_009 crossref_primary_10_3201_eid2805_211965 crossref_primary_10_1128_CVI_05528_11 crossref_primary_10_3390_vaccines6020027 crossref_primary_10_1016_j_vaccine_2011_11_114 crossref_primary_10_1093_infdis_jiy696 crossref_primary_10_1172_JCI122895 crossref_primary_10_1038_s41541_021_00377_6 crossref_primary_10_1038_s41591_019_0463_x crossref_primary_10_2807_1560_7917_ES2015_20_2_21011 crossref_primary_10_1111_irv_12411 crossref_primary_10_1007_s00103_012_1590_4 crossref_primary_10_3390_vaccines12101100 crossref_primary_10_1186_s13063_017_1808_8 crossref_primary_10_1080_21645515_2016_1219809 crossref_primary_10_1038_s41564_024_01732_8 crossref_primary_10_4049_jimmunol_1701276 crossref_primary_10_1126_sciadv_ads1267 crossref_primary_10_1016_j_virusres_2013_05_006 crossref_primary_10_1016_j_vaccine_2019_12_037 crossref_primary_10_1146_annurev_immunol_032414_112315 crossref_primary_10_1097_QAD_0b013e32835ab5b2 crossref_primary_10_1371_journal_pone_0100926 crossref_primary_10_7554_eLife_90091 crossref_primary_10_1093_infdis_jis360 crossref_primary_10_1111_1750_3841_15675 crossref_primary_10_12771_emj_2024_e35 crossref_primary_10_1016_j_vaccine_2015_04_059 crossref_primary_10_1007_s10238_023_01203_0 crossref_primary_10_1016_j_vaccine_2018_11_061 crossref_primary_10_4161_hv_8_1_18011 crossref_primary_10_1128_CVI_00297_16 crossref_primary_10_1098_rstb_2012_0200 crossref_primary_10_1128_mBio_00012_12 crossref_primary_10_1016_j_vaccine_2020_11_032 crossref_primary_10_1136_annrheumdis_2014_207191 crossref_primary_10_1038_s41598_024_83026_x crossref_primary_10_1016_j_vaccine_2014_05_027 crossref_primary_10_1016_j_it_2016_05_005 crossref_primary_10_1016_j_vaccine_2012_07_039 crossref_primary_10_1586_erv_11_101 crossref_primary_10_1016_j_vaccine_2025_126802 crossref_primary_10_1182_bloodadvances_2020003880 crossref_primary_10_1371_journal_pcbi_1007294 crossref_primary_10_1016_S0140_6736_10_62228_3 crossref_primary_10_14745_ccdr_v37i00a04 crossref_primary_10_1016_j_cmi_2019_06_013 crossref_primary_10_4161_hv_25580 crossref_primary_10_1016_j_vaccine_2015_03_031 crossref_primary_10_1093_cid_cix900 crossref_primary_10_1371_journal_pcbi_1006505 crossref_primary_10_1371_journal_pone_0210124 crossref_primary_10_3201_eid2404_171995 crossref_primary_10_1093_infdis_jiz327 crossref_primary_10_1371_journal_pcbi_1007840 crossref_primary_10_1371_journal_ppat_1006432 crossref_primary_10_1186_s12974_023_02945_0 crossref_primary_10_1080_22221751_2023_2290838 crossref_primary_10_1093_cid_ciaa1927 crossref_primary_10_3390_vaccines7010030 crossref_primary_10_1016_j_vaccine_2011_05_040 crossref_primary_10_1016_j_vaccine_2014_05_045 crossref_primary_10_1128_JVI_01202_17 crossref_primary_10_3390_vaccines12111275 crossref_primary_10_7554_eLife_62105 crossref_primary_10_1172_JCI148763 crossref_primary_10_1093_infdis_jiy013 crossref_primary_10_1186_s12879_019_4049_5 crossref_primary_10_1089_hum_2018_102 crossref_primary_10_3390_v13020199 crossref_primary_10_1371_journal_pone_0059077 crossref_primary_10_1016_j_vaccine_2015_08_065 crossref_primary_10_1371_journal_pone_0172008 crossref_primary_10_1586_eri_11_51 crossref_primary_10_1371_journal_pcbi_1012893 crossref_primary_10_1111_irv_12452 crossref_primary_10_1111_ajt_16295 crossref_primary_10_3390_vaccines2040707 crossref_primary_10_14776_piv_2019_26_e18 crossref_primary_10_4161_hv_25363 crossref_primary_10_1093_ofid_ofz383 crossref_primary_10_1126_science_1256427 crossref_primary_10_1080_21645515_2015_1011562 crossref_primary_10_1016_j_vaccine_2017_01_026 crossref_primary_10_1080_21645515_2017_1413518 crossref_primary_10_1136_jitc_2021_003428 crossref_primary_10_1371_journal_pone_0253028 crossref_primary_10_1371_journal_pone_0181738 crossref_primary_10_1186_1471_2458_12_417 crossref_primary_10_3390_microorganisms9112323 crossref_primary_10_3390_pathogens13020097 crossref_primary_10_1093_infdis_jit372 crossref_primary_10_1016_j_vaccine_2020_01_022 crossref_primary_10_1002_jmv_29266 crossref_primary_10_3390_vaccines12080943 crossref_primary_10_4178_epih_e2021076 crossref_primary_10_3390_vaccines7040215 crossref_primary_10_3390_pathogens8040238 crossref_primary_10_1038_s41392_022_00920_4 crossref_primary_10_3390_vaccines9121465 |
| Cites_doi | 10.1017/S0022172400053158 10.1002/sim.4780110204 10.1016/S0140-6736(06)68656-X 10.1017/S0022172400028990 10.1093/infdis/116.4.425 10.1214/07-AOAS132 10.1086/522428 10.1016/j.virusres.2004.02.025 10.1371/journal.pmed.0040218 10.1080/01621459.1987.10478458 10.1016/j.vaccine.2008.04.016 10.1111/1467-9868.00353 10.1093/biostatistics/1.1.49 10.4049/jimmunol.176.10.6333 10.1001/jama.1957.02980290006002 10.1016/j.virusres.2004.02.024 10.1017/S0022172400022610 10.1002/sim.2282 10.1016/S0264-410X(96)00302-7 10.1016/0264-410X(94)90056-6 10.1016/S0264-410X(03)00073-2 10.1002/sim.3122 10.1017/S0022172400063907 10.2307/1390675 10.1097/00006454-200101000-00013 10.1017/S0022172400028989 10.1016/S0197-2456(01)00153-2 10.1016/j.biologicals.2009.02.002 10.1002/sim.4780080407 10.1136/pgmj.49.569.159 10.1023/A:1008929526011 10.1201/9781482276596 10.1191/0962280204sm362ra 10.1093/oxfordjournals.aje.a112029 10.1093/oxfordjournals.aje.a113408 |
| ContentType | Journal Article |
| Copyright | Coudeville et al; licensee BioMed Central Ltd. 2010 COPYRIGHT 2010 BioMed Central Ltd. 2010 Coudeville et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2010 Coudeville et al; licensee BioMed Central Ltd. 2010 Coudeville et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Coudeville et al; licensee BioMed Central Ltd. 2010 – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: 2010 Coudeville et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2010 Coudeville et al; licensee BioMed Central Ltd. 2010 Coudeville et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/1471-2288-10-18 |
| DatabaseName | Springer Nature Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2288 |
| EndPage | 18 |
| ExternalDocumentID | oai_doaj_org_article_29eac57841f24acb8153ed474fcc6d18 10.1186/1471-2288-10-18 PMC2851702 2559563681 A223401598 20210985 10_1186_1471_2288_10_18 |
| Genre | Meta-Analysis Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM ADTOC AFFHD UNPAY |
| ID | FETCH-LOGICAL-c659t-1fa8dad6b077a0d5ab5b51cfce8fcdea2d3b9551fc3240d1e544c5cfa91432843 |
| IEDL.DBID | M48 |
| ISSN | 1471-2288 |
| IngestDate | Fri Oct 03 12:48:07 EDT 2025 Wed Oct 29 11:47:02 EDT 2025 Tue Sep 30 16:54:24 EDT 2025 Thu Sep 04 15:46:15 EDT 2025 Tue Oct 07 05:21:59 EDT 2025 Mon Oct 20 22:32:44 EDT 2025 Mon Oct 20 16:32:45 EDT 2025 Mon Jul 21 06:04:09 EDT 2025 Thu Apr 24 22:51:16 EDT 2025 Wed Oct 01 05:06:50 EDT 2025 Sat Sep 06 07:28:54 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Haemagglutination Inhibition Vaccine Strain Influenza Vaccine Vaccine Efficacy Influenza |
| Language | English |
| License | http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c659t-1fa8dad6b077a0d5ab5b51cfce8fcdea2d3b9551fc3240d1e544c5cfa91432843 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doaj.org/article/29eac57841f24acb8153ed474fcc6d18 |
| PMID | 20210985 |
| PQID | 915869101 |
| PQPubID | 42579 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_29eac57841f24acb8153ed474fcc6d18 unpaywall_primary_10_1186_1471_2288_10_18 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2851702 proquest_miscellaneous_733868065 proquest_journals_915869101 gale_infotracmisc_A223401598 gale_infotracacademiconefile_A223401598 pubmed_primary_20210985 crossref_citationtrail_10_1186_1471_2288_10_18 crossref_primary_10_1186_1471_2288_10_18 springer_journals_10_1186_1471_2288_10_18 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-03-08 |
| PublicationDateYYYYMMDD | 2010-03-08 |
| PublicationDate_xml | – month: 03 year: 2010 text: 2010-03-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC medical research methodology |
| PublicationTitleAbbrev | BMC Med Res Methodol |
| PublicationTitleAlternate | BMC Med Res Methodol |
| PublicationYear | 2010 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | Tanner, Wong (CR19) 1987; 82 Plotkin (CR26) 2001; 20 Farnik, Bruj (CR38) 1966; 116 Salk, Menke, Francis (CR8) 1945; 42 Freedman, Graubard, Schatzkin (CR11) 1992; 11 Hannoun, Megas, Piercy (CR6) 2004; 103 De Gruttola, Clax, DeMets, Downing, Ellenberg, Friedman (CR12) 2001; 22 Evans (CR37) 1975; 48 Brooks, Gelman (CR21) 1998; 7 Gilbert, Qin, Self (CR7) 2008; 27 Nauta, Beyer, Osterhaus (CR28) 2009; 37 Clark, Potter, Jennings, Nicholl, Langrick, Schild (CR33) 1983; 90 Potter, Jennings, Nicholson, Tyrrell, Dickinson (CR43) 1977; 79 Hirota, Kaji, Ide, Kajiwara, Kataoka, Goto (CR24) 1997; 15 Goodeve, Potter, Clark, Jennings, Schild, Yetts (CR40) 1983; 90 Buyse, Molenberghs, Burzykowski, Renard, Geys (CR13) 2000; 1 Kohberger, Jemiolo, Noriega (CR17) 2008; 26 Bresson, Perronne, Launay, Gerdil, Saville, Wood (CR31) 2006; 367 McElhaney, Xie, Hager, Barry, Wang, Kleppinger (CR27) 2006; 176 Dunning (CR16) 2006; 25 Riley, Wu, Leung (CR9) 2007; 4 Molenberghs, Burzykowski, Alonso, Buyse (CR15) 2004; 13 (CR3) 1997 Wood, Levandowski (CR4) 2003; 21 Lunn, Thomas, Best, Spiegelhalter (CR20) 2000; 10 Wood, Gaines-Das, Taylor, Chakraverty (CR29) 1994; 12 Spiegelhalter, Best, Carlin, Linde (CR23) 2002; 64 Gupta, Nadarajah (CR22) 2004 Greenberg, Couch, Kasel (CR41) 1974; 100 Prentice (CR10) 1989; 8 Eaton, Meiklejohn (CR36) 1945; 42 (CR1) 2008 Palmer, Dowdle, Coleman, Schild (CR2) 1975 Qin, Gilbert, Follman, Li (CR18) 2008; 2 Dowdle, Coleman, Mostow, Kaye, Schoenbaum (CR35) 1973; 49 de Jong, Palache, Beyer, Rimmelzwaan, Boon, Osterhaus (CR25) 2003; 115 Qin, Gilbert, Corey, McElrath, Self (CR14) 2007; 196 Bell, Ward, Kapikian, Shelokov, Reichelderfer, Huebner (CR32) 1957; 165 Fox, Cooney, Hall, Foy (CR39) 1982; 116 Hobson, Curry, Beare, Ward-Gardner (CR5) 1972; 70 Beyer, Palache, Luchters, Nauta, Osterhaus (CR30) 2004; 103 Clark, Potter, Jennings, Nicholl, Langrick, Schild (CR34) 1983; 90 Meiklejohn, Weiss, Shragg, Lennette (CR42) 1952; 55 Y Hirota (421_CR24) 1997; 15 LS Freedman (421_CR11) 1992; 11 JE McElhaney (421_CR27) 2006; 176 D Hobson (421_CR5) 1972; 70 RC Kohberger (421_CR17) 2008; 26 MD Eaton (421_CR36) 1945; 42 AS Evans (421_CR37) 1975; 48 G Molenberghs (421_CR15) 2004; 13 AK Gupta (421_CR22) 2004 AJ Dunning (421_CR16) 2006; 25 DJ Lunn (421_CR20) 2000; 10 A Goodeve (421_CR40) 1983; 90 CW Potter (421_CR43) 1977; 79 S Riley (421_CR9) 2007; 4 JP Fox (421_CR39) 1982; 116 Committee for Proprietary Medicinal Products (CPMP) (421_CR3) 1997 C Hannoun (421_CR6) 2004; 103 L Qin (421_CR14) 2007; 196 WR Dowdle (421_CR35) 1973; 49 D Spiegelhalter (421_CR23) 2002; 64 A Clark (421_CR34) 1983; 90 JM Wood (421_CR4) 2003; 21 JA Bell (421_CR32) 1957; 165 L Qin (421_CR18) 2008; 2 JL Bresson (421_CR31) 2006; 367 G Meiklejohn (421_CR42) 1952; 55 JE Salk (421_CR8) 1945; 42 DF Palmer (421_CR2) 1975 MA Tanner (421_CR19) 1987; 82 PB Gilbert (421_CR7) 2008; 27 J Farnik (421_CR38) 1966; 116 SP Brooks (421_CR21) 1998; 7 JC de Jong (421_CR25) 2003; 115 JJ Nauta (421_CR28) 2009; 37 WE Beyer (421_CR30) 2004; 103 SB Greenberg (421_CR41) 1974; 100 WHO (421_CR1) 2008 A Clark (421_CR33) 1983; 90 RL Prentice (421_CR10) 1989; 8 M Buyse (421_CR13) 2000; 1 JM Wood (421_CR29) 1994; 12 SA Plotkin (421_CR26) 2001; 20 VG De Gruttola (421_CR12) 2001; 22 16158409 - Stat Med. 2006 May 15;25(9):1485-97 6822725 - J Hyg (Lond). 1983 Feb;90(1):107-15 4479059 - Am J Epidemiol. 1974 Sep;100(3):209-15 11578783 - Control Clin Trials. 2001 Oct;22(5):485-502 17579511 - PLoS Med. 2007 Jun;4(6):e218 19268607 - Biologicals. 2009 Aug;37(4):216-21 15163500 - Virus Res. 2004 Jul;103(1-2):125-32 16670345 - J Immunol. 2006 May 15;176(10):6333-9 12933525 - Biostatistics. 2000 Mar;1(1):49-67 18495303 - Vaccine. 2008 Jun 25;26(27-28):3516-21 15198486 - Stat Methods Med Res. 2004 Jun;13(3):177-206 169640 - Yale J Biol Med. 1975 Jul;48(3):201-9 16714186 - Lancet. 2006 May 20;367(9523):1657-64 9261942 - Vaccine. 1997 Jun;15(9):962-7 11176570 - Pediatr Infect Dis J. 2001 Jan;20(1):63-75 1579756 - Stat Med. 1992 Jan 30;11(2):167-78 2727467 - Stat Med. 1989 Apr;8(4):431-40 15163501 - Virus Res. 2004 Jul;103(1-2):133-8 270523 - J Hyg (Lond). 1977 Dec;79(3):321-32 8147099 - Vaccine. 1994 Feb;12(2):167-74 15088777 - Dev Biol (Basel). 2003;115:63-73 5928620 - J Infect Dis. 1966 Oct;116(4):425-8 4803439 - Postgrad Med J. 1973 Mar;49(569):159-63 17979212 - Stat Med. 2008 Oct 15;27(23):4758-78 7114034 - Am J Epidemiol. 1982 Aug;116(2):228-42 14885161 - Am J Hyg. 1952 Jan;55(1):1-11 19079758 - Ann Appl Stat. 2008 Mar;2(1):386-407 17922394 - J Infect Dis. 2007 Nov 1;196(9):1304-12 4509641 - J Hyg (Lond). 1972 Dec;70(4):767-77 13475045 - J Am Med Assoc. 1957 Nov 16;165(11):1366-73 6863910 - J Hyg (Lond). 1983 Jun;90(3):361-70 6863909 - J Hyg (Lond). 1983 Jun;90(3):351-9 12686095 - Vaccine. 2003 May 1;21(16):1786-8 |
| References_xml | – volume: 79 start-page: 321 year: 1977 end-page: 332 ident: CR43 article-title: Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines publication-title: J Hyg (Lond) doi: 10.1017/S0022172400053158 – volume: 11 start-page: 167 year: 1992 end-page: 178 ident: CR11 article-title: Statistical validation of intermediate endpoints for chronic diseases publication-title: Stat Med doi: 10.1002/sim.4780110204 – volume: 367 start-page: 1657 year: 2006 end-page: 1664 ident: CR31 article-title: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(06)68656-X – volume: 90 start-page: 361 year: 1983 end-page: 370 ident: CR34 article-title: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity publication-title: J Hyg (Lond) doi: 10.1017/S0022172400028990 – volume: 116 start-page: 228 year: 1982 end-page: 242 ident: CR39 article-title: Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness publication-title: Am J Epidemiol – volume: 116 start-page: 425 year: 1966 end-page: 428 ident: CR38 article-title: An outbreak of influenza A2 in a population with a known antibody profile publication-title: J Infect Dis doi: 10.1093/infdis/116.4.425 – volume: 2 start-page: 386 year: 2008 end-page: 407 ident: CR18 article-title: Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model publication-title: The annals of applied statistics doi: 10.1214/07-AOAS132 – volume: 196 start-page: 1304 year: 2007 end-page: 1312 ident: CR14 article-title: A framework for assessing immunological correlates of protection in vaccine trials publication-title: J Infect Dis doi: 10.1086/522428 – volume: 103 start-page: 133 year: 2004 end-page: 138 ident: CR6 article-title: Immunogenicity and protective efficacy of influenza vaccination publication-title: Virus Res doi: 10.1016/j.virusres.2004.02.025 – volume: 4 start-page: e218 year: 2007 ident: CR9 article-title: Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate publication-title: PLoS Med doi: 10.1371/journal.pmed.0040218 – volume: 82 start-page: 528 year: 1987 end-page: 550 ident: CR19 article-title: The calculation of posterior distributions by data augmentation publication-title: J Am Stat Assoc doi: 10.1080/01621459.1987.10478458 – volume: 26 start-page: 3516 year: 2008 end-page: 3521 ident: CR17 article-title: Prediction of pertussis vaccine efficacy using a correlates of protection model publication-title: Vaccine doi: 10.1016/j.vaccine.2008.04.016 – volume: 64 start-page: 583 year: 2002 end-page: 639 ident: CR23 article-title: Bayesian measures of model complexity and fit (with discussion) publication-title: Journal of the Royal Statistical Society, Series B (Statistical Methodology) doi: 10.1111/1467-9868.00353 – volume: 48 start-page: 201 year: 1975 end-page: 209 ident: CR37 article-title: Serologic studies of acute respiratory infections in military personnel publication-title: Yale J Biol Med – volume: 1 start-page: 49 year: 2000 end-page: 67 ident: CR13 article-title: The validation of surrogate endpoints in meta-analyses of randomized experiments publication-title: Biostatistics doi: 10.1093/biostatistics/1.1.49 – year: 2008 ident: CR1 article-title: Influenza factsheet publication-title: Factsheet number 211 – volume: 176 start-page: 6333 year: 2006 end-page: 6339 ident: CR27 article-title: T cell responses are better correlates of vaccine protection in the elderly publication-title: J Immunol doi: 10.4049/jimmunol.176.10.6333 – volume: 165 start-page: 1366 year: 1957 end-page: 1373 ident: CR32 article-title: Artificially induced Asian influenza in vaccinated and unvaccinated volunteers publication-title: J Am Med Assoc doi: 10.1001/jama.1957.02980290006002 – volume: 103 start-page: 125 year: 2004 end-page: 132 ident: CR30 article-title: Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? publication-title: Virus Res doi: 10.1016/j.virusres.2004.02.024 – volume: 55 start-page: 1 year: 1952 end-page: 11 ident: CR42 article-title: Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination publication-title: Am J Hyg – volume: 70 start-page: 767 year: 1972 end-page: 777 ident: CR5 article-title: The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses publication-title: J Hyg (Lond) doi: 10.1017/S0022172400022610 – volume: 100 start-page: 209 year: 1974 end-page: 215 ident: CR41 article-title: An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness publication-title: Am J Epidemiol – year: 1997 ident: CR3 article-title: Note for Guidance on Harmonisation of Requirements for Influenza Vaccines publication-title: EMEA – year: 1975 ident: CR2 publication-title: Advanced laboratory technicals for immunological diagnostic – volume: 25 start-page: 1485 year: 2006 end-page: 1497 ident: CR16 article-title: A model for immunological correlates of protection publication-title: Stat Med doi: 10.1002/sim.2282 – volume: 15 start-page: 962 year: 1997 end-page: 967 ident: CR24 article-title: Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness publication-title: Vaccine doi: 10.1016/S0264-410X(96)00302-7 – volume: 42 start-page: 57 year: 1945 end-page: 93 ident: CR8 article-title: A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza publication-title: Am J Hyg – volume: 12 start-page: 167 year: 1994 end-page: 174 ident: CR29 article-title: Comparison of influenza serological techniques by international collaborative study publication-title: Vaccine doi: 10.1016/0264-410X(94)90056-6 – volume: 21 start-page: 1786 year: 2003 end-page: 1788 ident: CR4 article-title: The influenza vaccine licensing process publication-title: Vaccine doi: 10.1016/S0264-410X(03)00073-2 – volume: 27 start-page: 4758 year: 2008 end-page: 4778 ident: CR7 article-title: Evaluating a surrogate endpoint at three levels, with application to vaccine development publication-title: Stat Med doi: 10.1002/sim.3122 – year: 2004 ident: CR22 publication-title: Handbook of Beta Distribution and Its Applications – volume: 90 start-page: 107 year: 1983 end-page: 115 ident: CR40 article-title: A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection publication-title: J Hyg (Lond) doi: 10.1017/S0022172400063907 – volume: 7 start-page: 434 year: 1998 end-page: 455 ident: CR21 article-title: Alternative methods for monitoring convergence of iterative simulations publication-title: Journal of Computational and Graphical Statistics doi: 10.2307/1390675 – volume: 20 start-page: 63 year: 2001 end-page: 75 ident: CR26 article-title: Immunologic correlates of protection induced by vaccination publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200101000-00013 – volume: 90 start-page: 351 year: 1983 end-page: 359 ident: CR33 article-title: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity publication-title: J Hyg (Lond) doi: 10.1017/S0022172400028989 – volume: 22 start-page: 485 year: 2001 end-page: 502 ident: CR12 article-title: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop publication-title: Control Clin Trials doi: 10.1016/S0197-2456(01)00153-2 – volume: 37 start-page: 216 year: 2009 end-page: 221 ident: CR28 article-title: On the relationship between mean antibody level, seroprotection and clinical protection from influenza publication-title: Biologicals doi: 10.1016/j.biologicals.2009.02.002 – volume: 8 start-page: 431 year: 1989 end-page: 440 ident: CR10 article-title: Surrogate endpoints in clinical trials: definition and operational criteria publication-title: Stat Med doi: 10.1002/sim.4780080407 – volume: 13 start-page: 177 year: 2004 end-page: 206 ident: CR15 article-title: A perspective on surrogate endpoints in controlled clinical trials publication-title: Stat Methods Med Res – volume: 42 start-page: 28 year: 1945 end-page: 44 ident: CR36 article-title: Vaccination against Influenza. A study in California during the epidemic of 1943-44 publication-title: Am J Hyg – volume: 49 start-page: 159 year: 1973 end-page: 163 ident: CR35 article-title: Inactivated influenza vaccines. 2. Laboratory indices of protection publication-title: Postgrad Med J doi: 10.1136/pgmj.49.569.159 – volume: 115 start-page: 63 year: 2003 end-page: 73 ident: CR25 article-title: Haemagglutination-inhibiting antibody to influenza virus publication-title: Dev Biol (Basel) – volume: 10 start-page: 325 year: 2000 end-page: 337 ident: CR20 article-title: a Bayesian modelling framework: concepts, structure, and extensibility publication-title: Statistics and Computing doi: 10.1023/A:1008929526011 – volume: 90 start-page: 351 year: 1983 ident: 421_CR33 publication-title: J Hyg (Lond) doi: 10.1017/S0022172400028989 – volume: 11 start-page: 167 year: 1992 ident: 421_CR11 publication-title: Stat Med doi: 10.1002/sim.4780110204 – volume-title: Handbook of Beta Distribution and Its Applications year: 2004 ident: 421_CR22 doi: 10.1201/9781482276596 – volume: 13 start-page: 177 year: 2004 ident: 421_CR15 publication-title: Stat Methods Med Res doi: 10.1191/0962280204sm362ra – volume: 8 start-page: 431 year: 1989 ident: 421_CR10 publication-title: Stat Med doi: 10.1002/sim.4780080407 – volume: 367 start-page: 1657 year: 2006 ident: 421_CR31 publication-title: Lancet doi: 10.1016/S0140-6736(06)68656-X – volume: 64 start-page: 583 year: 2002 ident: 421_CR23 publication-title: Journal of the Royal Statistical Society, Series B (Statistical Methodology) doi: 10.1111/1467-9868.00353 – volume: 20 start-page: 63 year: 2001 ident: 421_CR26 publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200101000-00013 – volume: 79 start-page: 321 year: 1977 ident: 421_CR43 publication-title: J Hyg (Lond) doi: 10.1017/S0022172400053158 – volume-title: EMEA year: 1997 ident: 421_CR3 – volume: 55 start-page: 1 year: 1952 ident: 421_CR42 publication-title: Am J Hyg – volume: 26 start-page: 3516 year: 2008 ident: 421_CR17 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.04.016 – volume: 82 start-page: 528 year: 1987 ident: 421_CR19 publication-title: J Am Stat Assoc doi: 10.1080/01621459.1987.10478458 – volume: 42 start-page: 28 year: 1945 ident: 421_CR36 publication-title: Am J Hyg – volume: 42 start-page: 57 year: 1945 ident: 421_CR8 publication-title: Am J Hyg – volume: 116 start-page: 425 year: 1966 ident: 421_CR38 publication-title: J Infect Dis doi: 10.1093/infdis/116.4.425 – volume: 48 start-page: 201 year: 1975 ident: 421_CR37 publication-title: Yale J Biol Med – volume: 2 start-page: 386 year: 2008 ident: 421_CR18 publication-title: The annals of applied statistics doi: 10.1214/07-AOAS132 – volume: 90 start-page: 361 year: 1983 ident: 421_CR34 publication-title: J Hyg (Lond) doi: 10.1017/S0022172400028990 – volume-title: Factsheet number 211 year: 2008 ident: 421_CR1 – volume: 7 start-page: 434 year: 1998 ident: 421_CR21 publication-title: Journal of Computational and Graphical Statistics doi: 10.2307/1390675 – volume: 115 start-page: 63 year: 2003 ident: 421_CR25 publication-title: Dev Biol (Basel) – volume: 196 start-page: 1304 year: 2007 ident: 421_CR14 publication-title: J Infect Dis doi: 10.1086/522428 – volume: 1 start-page: 49 year: 2000 ident: 421_CR13 publication-title: Biostatistics doi: 10.1093/biostatistics/1.1.49 – volume: 4 start-page: e218 year: 2007 ident: 421_CR9 publication-title: PLoS Med doi: 10.1371/journal.pmed.0040218 – volume: 165 start-page: 1366 year: 1957 ident: 421_CR32 publication-title: J Am Med Assoc doi: 10.1001/jama.1957.02980290006002 – volume: 100 start-page: 209 year: 1974 ident: 421_CR41 publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a112029 – volume: 90 start-page: 107 year: 1983 ident: 421_CR40 publication-title: J Hyg (Lond) doi: 10.1017/S0022172400063907 – volume-title: Advanced laboratory technicals for immunological diagnostic year: 1975 ident: 421_CR2 – volume: 116 start-page: 228 year: 1982 ident: 421_CR39 publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a113408 – volume: 103 start-page: 125 year: 2004 ident: 421_CR30 publication-title: Virus Res doi: 10.1016/j.virusres.2004.02.024 – volume: 27 start-page: 4758 year: 2008 ident: 421_CR7 publication-title: Stat Med doi: 10.1002/sim.3122 – volume: 49 start-page: 159 year: 1973 ident: 421_CR35 publication-title: Postgrad Med J doi: 10.1136/pgmj.49.569.159 – volume: 22 start-page: 485 year: 2001 ident: 421_CR12 publication-title: Control Clin Trials doi: 10.1016/S0197-2456(01)00153-2 – volume: 37 start-page: 216 year: 2009 ident: 421_CR28 publication-title: Biologicals doi: 10.1016/j.biologicals.2009.02.002 – volume: 176 start-page: 6333 year: 2006 ident: 421_CR27 publication-title: J Immunol doi: 10.4049/jimmunol.176.10.6333 – volume: 12 start-page: 167 year: 1994 ident: 421_CR29 publication-title: Vaccine doi: 10.1016/0264-410X(94)90056-6 – volume: 70 start-page: 767 year: 1972 ident: 421_CR5 publication-title: J Hyg (Lond) doi: 10.1017/S0022172400022610 – volume: 25 start-page: 1485 year: 2006 ident: 421_CR16 publication-title: Stat Med doi: 10.1002/sim.2282 – volume: 15 start-page: 962 year: 1997 ident: 421_CR24 publication-title: Vaccine doi: 10.1016/S0264-410X(96)00302-7 – volume: 21 start-page: 1786 year: 2003 ident: 421_CR4 publication-title: Vaccine doi: 10.1016/S0264-410X(03)00073-2 – volume: 103 start-page: 133 year: 2004 ident: 421_CR6 publication-title: Virus Res doi: 10.1016/j.virusres.2004.02.025 – volume: 10 start-page: 325 year: 2000 ident: 421_CR20 publication-title: Statistics and Computing doi: 10.1023/A:1008929526011 – reference: 15088777 - Dev Biol (Basel). 2003;115:63-73 – reference: 9261942 - Vaccine. 1997 Jun;15(9):962-7 – reference: 16158409 - Stat Med. 2006 May 15;25(9):1485-97 – reference: 17979212 - Stat Med. 2008 Oct 15;27(23):4758-78 – reference: 2727467 - Stat Med. 1989 Apr;8(4):431-40 – reference: 17579511 - PLoS Med. 2007 Jun;4(6):e218 – reference: 1579756 - Stat Med. 1992 Jan 30;11(2):167-78 – reference: 6822725 - J Hyg (Lond). 1983 Feb;90(1):107-15 – reference: 15163501 - Virus Res. 2004 Jul;103(1-2):133-8 – reference: 8147099 - Vaccine. 1994 Feb;12(2):167-74 – reference: 12686095 - Vaccine. 2003 May 1;21(16):1786-8 – reference: 13475045 - J Am Med Assoc. 1957 Nov 16;165(11):1366-73 – reference: 18495303 - Vaccine. 2008 Jun 25;26(27-28):3516-21 – reference: 16670345 - J Immunol. 2006 May 15;176(10):6333-9 – reference: 19268607 - Biologicals. 2009 Aug;37(4):216-21 – reference: 169640 - Yale J Biol Med. 1975 Jul;48(3):201-9 – reference: 12933525 - Biostatistics. 2000 Mar;1(1):49-67 – reference: 16714186 - Lancet. 2006 May 20;367(9523):1657-64 – reference: 4479059 - Am J Epidemiol. 1974 Sep;100(3):209-15 – reference: 6863909 - J Hyg (Lond). 1983 Jun;90(3):351-9 – reference: 15163500 - Virus Res. 2004 Jul;103(1-2):125-32 – reference: 4803439 - Postgrad Med J. 1973 Mar;49(569):159-63 – reference: 6863910 - J Hyg (Lond). 1983 Jun;90(3):361-70 – reference: 19079758 - Ann Appl Stat. 2008 Mar;2(1):386-407 – reference: 5928620 - J Infect Dis. 1966 Oct;116(4):425-8 – reference: 11578783 - Control Clin Trials. 2001 Oct;22(5):485-502 – reference: 17922394 - J Infect Dis. 2007 Nov 1;196(9):1304-12 – reference: 4509641 - J Hyg (Lond). 1972 Dec;70(4):767-77 – reference: 270523 - J Hyg (Lond). 1977 Dec;79(3):321-32 – reference: 11176570 - Pediatr Infect Dis J. 2001 Jan;20(1):63-75 – reference: 15198486 - Stat Methods Med Res. 2004 Jun;13(3):177-206 – reference: 14885161 - Am J Hyg. 1952 Jan;55(1):1-11 – reference: 7114034 - Am J Epidemiol. 1982 Aug;116(2):228-42 |
| SSID | ssj0017836 |
| Score | 2.4407172 |
| SecondaryResourceType | review_article |
| Snippet | Background
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against... Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza... Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against... Abstract Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity... Abstract Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 18 |
| SubjectTerms | Adult Antibodies Antibodies, Viral - blood Bayes Theorem Bayesian statistical decision theory Censorship Diagnosis Drug therapy Health aspects Health Sciences Hemagglutinins - immunology Humans Illnesses Immunization Influenza Influenza, Human - immunology Medicine Medicine & Public Health Methods Models, Theoretical Mortality Pandemics Properties Research Article Statistical Theory and Methods Statistics for Life Sciences Theory of Medicine/Bioethics Vaccination Vaccines Viral antibodies Writing |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZQDywHxE5oQT4gQQ-hiR0nNreCqCqkcqJSb5bXmUjTzIjOCA1_iT_Je4knnQFVvXAcL1L8_Pkt8zZC3nrulOch5JxFmwP3q3LJQpVbzm1ZGMzOREPx7Ft9el59vRAXW62-MCZsKA88EO6IKWANAr1jkVXGWQlPNPiqqaJztS_7NN9Cqo0xlfwHmJvQ5xU1Zc6YlKmoTynro3EMORD2-tiSR33Z_n-Z85Z0-jtycnSfPiD3Vt3CrH-a2WxLQp08Ig-TakmPhyM9JndC94TcPUvO86fk9xj4Nm0XNAVo0akJl2YyQQAOfwzmbTdtbYvh0BTI3tq5X1PAFNjl8NvTTS4lTSUeYAs1E9OCnknboeXJL_OR-utopH7blqecziM11Jp1wAxOCtLSA6dOkSW0783zjJyffPn--TRPvRpyVwu1zMtopDe-tkXTmMILY4UVpYsuyOh8MMxzq0A7iw4rAPoyiKpywkWjQGEDEcmfk71u3oWXhHLmrQfVxNjoK9aUBqRrJVXhojBSiSIjHzY3pl0qZI79NGa6N2hkrfGKNV5xPyIz8n7csBhqeNy89BNCYFyGxbf7AYCkTpDUt0EyI-8QQBpZBHyYMynTAY6Hxbb0MahkYNYKBSsPdlbC03Y70_sbCOrEWq60KoWsQckrM0LHWdyI0XJdmK-udMO5rNFjnpEXA17HAzG08ZWEmWYHyTsn3p3p2mlfdpyBct4ULCOHG8xff9SN5DwcH8VtpH_1P0i_T-4P4R08L-QB2Vv-WIXXoDUu7ZueQfwBk71p6w priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEF_qFfx4EL-qsVX2QdA-xCa72WQjiLTSUoQrIhb6FvYrd4EzOds75PyX_CedSTbpnVJ9vOzusZuZnY_MzG8IeWW5yS13LuSs1CFIvySUzCWh5lzHkcLqTHQUx2fp6Xny6UJcbJFxXwuDaZW9TGwFtW0MfiM_yGMhU9Bt8Yf59xCbRmFwte-goXxnBfu-RRi7RbYZAmONyPbR8dnnL0NYAUsWPL5PLNODGPYWMiZbgFNs-7GmmloE_7_l9Jqi-jOJcoik3iN3lvVcrX6o2WxNWZ08IPe9lUkPO7Z4SLZc_YjcHvs4-mPya8iBm1Zz6nO16FS5b2oyQV7svhGGVT2tdIWZ0RQoUOnGriiwF7jo8NvSvqySerQHWELVRFVgctKq637yU72j9joxqV22FjSnTUkV1WrlsJiTguK0ILR9kglt2_Q8Iecnx18_noa-bUNoUpEvwrhU0iqb6ijLVGSF0kKL2JTGydJYp5jlOgcylQbBAG3sRJIYYUqVg-0G2pLvkFHd1O4ZoZxZbcFKUbq0CctiBWRNZB6ZUiiZiyggb3uKFcZjmmNrjVnR-jYyLZDEBZK4fSID8mZYMO_gPG6eeoQsMExDHO72QXM5Kfy1LlgOiktg7LZkiTJaggJxNsmS0pjU4p-8RgYqUFrAxozyRQ9wPMTdKg7BOgMPV-Qwc29jJtxyszG827Ng4aXMVTHciYDQYRQXYuJc7ZrlVZFxLlMMngfkacevw4EYuvu5hJFsg5M3Trw5UlfTFoGcgZ2eRSwg-z3PX2_qxte5P1yK_7365_887C6526Vw8DCSe2S0uFy6F2AZLvRLf99_A1-fZSc priority: 102 providerName: ProQuest – databaseName: Springer Nature Open Access Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSFAOiDehBfmABD2EJnacONxKRVUhlROVerP83I20ZFd0V9Xyl_iTzCTedANUiGNsTxTb43lkZj4T8sZxWzvufcpZMClIvyKVzBep4dzkmcbqTHQUz76Up-fF5wtxEUGSsBZmO36fy_IwB_KUMdlhkObyNrkDGqrsorLl8RAuwFKEiNvzF6KRyumQ-f-Uv1sK6PfkyCFCep_cW7ULvb7Ss9mWEjp5SB5E65Ee9dv9iNzy7WNy9yzGx5-Qn0Nu27RZ0JiDRafaf9OTCfJY_-8vbdppYxrMeKawso2ZuzUFtgHXG54d3ZRL0ojiACRUT3QDpiRt-ltNfugP1F0nHHVkW8FwOg9UU6PXHos0KShEB8I4Jo_Q7vqdp-T85NPX49M0XseQ2lLUyzQPWjrtSpNVlc6c0EYYkdtgvQzWec0cNzUYYMEiyJ_LvSgKK2zQNdhkoAX5M7LTzlv_glDOnHFgfWgTXMGqXIMCLWSd2SC0rEWWkPebHVM2YpXjlRkz1fksslS4xQq3uGuRCXk3ECx6mI6bh35EFhiGIb521wBsp-JxVawGhSQwJhtYoa2RoBi8K6oiWFs6fMlbZCCFUgA-zOpYzADTQzwtdQRWF3iuooaR-6ORcHrtqHtvw4IqSo9LVedClmDH5QmhQy8SYkJc6-erS1VxLksMiifkec-vw4QYuvG1hJ5qxMmjGY972mbaIYszsL-rjCXkYMPz1x9143IeDIfiX0v_8j_eu0d2-0QNnmZyn-wsv6_8K7D_luZ1d_Z_AdKkVi0 priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6VVOJx4FkgtKA9IEEPTu1dr73mFhBVhdTCgUrlZO0zsUjtKE2E0r_En2TWXrtxoUJIHOOddfYxOw_vzDcIvdZUZZoaE1BiZQDSLw44MXEgKZVRKFx2pnMUj0-So9P40xk720Kf21wYea5AC4Cn2RRQrmajzTT0WZPl4KoomMXBXNvm0PPkIIK_CQjhNVZpxG-h7YSBcT5A26cnX8bf6hwjT-EBfv7Qq6ebagj_3wX1hqa6HkXZXaXeQ3dW5Vysf4jZbENbHT5A83aeTZDK99FqKUfq8hoE5H9ciIfovrds8bhhxUdoy5SP0e1jf3f_BP3s4u6mxRz7-DA8FeZcTCaO_5vvkkFRTgtZuGhsDLteyEqvMbA0jBF-a9ymcmKPMAFdsJiIAsxcXDQVVy7FO6yvgqHqbhsX9biyWGAp1sYlkGJQ1hoUhQ9swXVpoB10evjx64ejwJeKCBTs8zKIrOBa6ESGaSpCzYRkkkXKKsOt0kYQTWUGxqFVDoBQR4bFsWLKigzsRdDQ9CkalFVpniNMiZYaLCMhrY5JGglQ7jHPQmWZ4BkLh2jUMkmuPI66K-cxy2t_iie524LcbUH9hA_R267DvIEQuZn0veO6jsxhf9cPqsUk96IkJxkoS-buiy2JhZIclJbRcRpbpRLtXvLG8WzuJBQMTAmfaAHTc1hf-RgsQvCqWQaUez1KkCyq17zbcn3uJdtFnkWMJ2BjRkOEu1bX0QXrlaZaXeQppTxxF_ZD9Kw5It2EiPvEkHFoSXuHpzfjfktZTGvUcwK-QRqSIdpvj9nVoG5czv3uHP5t6V_8A-0uutsEkdAg5HtosFyszEuwTZfylZc3vwCDPY3f priority: 102 providerName: Unpaywall |
| Title | Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model |
| URI | https://link.springer.com/article/10.1186/1471-2288-10-18 https://www.ncbi.nlm.nih.gov/pubmed/20210985 https://www.proquest.com/docview/915869101 https://www.proquest.com/docview/733868065 https://pubmed.ncbi.nlm.nih.gov/PMC2851702 https://bmcmedresmethodol.biomedcentral.com/counter/pdf/10.1186/1471-2288-10-18 https://doaj.org/article/29eac57841f24acb8153ed474fcc6d18 |
| UnpaywallVersion | publishedVersion |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: ABDBF dateStart: 20010101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1471-2288 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: M48 dateStart: 20011101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: C6C dateStart: 20010112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Za9tAEF6aBHo8lN5Rk5p9KLR5UKJrpVWhFNskhIJNCDW4fRF7yRa4suPYtO5f6p_sjC7bbUxfBNLuSnvM7MxoZr8h5K32Vax9Y2zfS6UNu19gc88EtvR96ToCT2eiodjrh5eD4POQDdfpgKoJvL3TtMN8UoP55PTnzeoTMPzHguF5eObCJ2zP4wVOqcv3yAGIqRjzOPSCtUsBjytU2D53NEJQYDR_YkyqvCGhCiD_f7frDXn1dyxl41B9RB4s85lY_RCTyYbMunhCHlfKJm2X1PGU3DP5M3K_V7nTn5PfTSjcOJvRKmSLjoX5LkYjJMnyV6Gd5eNMZhggTWEhMjnVKwpUBpY63Gtan66kFegDNKFiJDLQPGlWJkH5JT5QvY5PKppt-M7pNKWCSrEyeKaTgvzUsHdXsSa0yNbzggwuzr90L-0qe4OtQhYvbDcVXAsdSieKhKOZkEwyV6XK8FRpIzztyxj0tVQhJqB2DQsCxVQqYlDhQGj6L8l-Ps3NIaG-p6UGZUXIVAde5AqQtwGPHZUywWPmWOS0XrFEVdDmmGFjkhQmDg8TXO0EV7t4wi3yvmkwK1E9dlftIAk01RCOu3gwnY-SirsTLwb5xdCFm3qBUJKDHDE6iIJUqVDjS94hASVIxtAxJaqzDzA8hN9K2qCkgaHLYqh5vFUTmF1tFR_VJJjUvJLELuMhqH2uRWhTig0xfi430-VtEvk-D9GHbpFXJb02A6rJ3iLRFiVvjXi7JM_GBRC5B-p65HgWOalpft2pndN50jDF_6b-9c6-HpGHZRSHbzv8mOwv5kvzBpTDhWyRvWgYtchB57x_dQ133bDbKn60tIrtAK7XnW9QPuhftb_-AW43aDI |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtNAdFRaicIBsRNaYA4g6MHUHm9jpAq10KqlTYRQK_VmZnNiKdghi6rwS3wD_8Z79thNQIVTj55Nnnlv3jJvI-Sl9lWifWMcn2XSAeoXOJyZwJG-Lz1XYHQmKordXnR4Fnw6D89XyK8mFgbdKhuaWBFqXSp8I99OvJBHwNu896PvDhaNQuNqU0FD2MoKeqfKMGbjOo7N_AI0uMnO0UcA9yvGDvZPPxw6tsiAo6IwmTpeJrgWOpJuHAtXh0KGMvRUpgzPlDaCaV8msGimMHWd9kwYBCpUmUhA0gDa7sO6N8ha4AcJ6H5re_u9z19aMwaGSNh8Qh6Ptj04C4cxXiVUxTIjC6ywqhjwN19YYIx_Om22ltvbZH1WjMT8QgyHC8zx4C65Y6Vauluj4T2yYor75GbX2u0fkJ-tz90gH1HrG0YHwnwT_T7ifv0m6eTFIJc5emJTgHguSz2ngM5jM4FvTZswTmqzS8AUKvoiBxGX5nW1lR_iHdWXjlDVtAUjPS0zKqgUc4PBoxQYtQYmYZ1aaFUW6CE5uxYIPiKrRVmYJ4T6TEsNUpGQmQ5Y7Alg7AFPXJWFgieh2yFvG4ilyuZQx1Iew7TSpXiUIohTBHHVwjvkTTthVKcPuXroHqJAOwzzflcN5bifWjKSsgQYZYi24owFQkkODMvoIA4ypSKNi7xGBEqROsGPKWGDLGB7mOcr3QVpEDTqMIGRm0sjgaqope6NBgVTS9UmaXsHO4S2vTgRHfUKU84maez7PEJjfYc8rvG13RDD54WEQ0-8hMlLO17uKfJBlfGcgV4Qu6xDthqcv_ypK49zq70U_zv6p__c7AuyfnjaPUlPjnrHG-RW7T7iOy7fJKvT8cw8A6l0Kp_bu0_J1-smN78BpbSkBw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSAUOiDdLC_iABD2kTZw4cbiVhao8WnGgUm-Wn7uRluyquyu0_CX-JDOJk-4CFeKY2GPF9ngemZnPhLy0qSlt6lyUMq8jkH5ZJJjLIp2mOokVVmeio3hymh-fZR_P-XnIzZl32e5dSLKtaUCUpnpxMLO-PeIiP0hg0Igx0SCTJuI6uZGBasMLDIb5sA8iYIFCQPP5C9GGImrw-v-Uymtq6feUyT5uepvcXNYztfquJpM11XR0l9wJNiU9bJngHrnm6vtk-yREzR-Qn33G27ia0ZCZRcfKfVOjEXJe-0cwqupxpSvMg6aw3pWe2hUFZgKHHJ4t7YooacB2ABKqRqoCA5NW7V0nP9Qbai_TkBqytRA5nXqqqFYrh6WbFNSkBREdUkpocynPQ3J29P7r8DgKlzREJuflIkq8ElbZXMdFoWLLleaaJ8YbJ7yxTjGb6hLMMm8Q-s8mjmeZ4carEiw10I3pI7JVT2v3hNCUWW3BJlHa24wViQK1mokyNp4rUfJ4QPa7HZMmIJjjRRoT2XgyIpe4xRK3uHkjBuR1TzBrwTuu7voWWaDvhqjbzYvpxUiGQyxZCWqKY6TWs0wZLUBdOJsVmTcmtzjIK2QgibIBPsyoUOIA00OULXkIthj4s7yEnrsbPeFMm43mnY4FZZApc1kmXORg3SUDQvtWJMQ0udpNl3NZpKnIMVQ-II9bfu0nxNC5LwW0FBucvDHjzZa6Gjd44wys8iJmA7LX8fzlR125nHv9ofjX0j_9j3FfkO0v747k5w-nn3bIrTaTI41isUu2FhdL9wwMxIV-3oiBX7ivYWM |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6VVOJx4FkgtKA9IEEPTu1dr73mFhBVhdTCgUrlZO0zsUjtKE2E0r_En2TWXrtxoUJIHOOddfYxOw_vzDcIvdZUZZoaE1BiZQDSLw44MXEgKZVRKFx2pnMUj0-So9P40xk720Kf21wYea5AC4Cn2RRQrmajzTT0WZPl4KoomMXBXNvm0PPkIIK_CQjhNVZpxG-h7YSBcT5A26cnX8bf6hwjT-EBfv7Qq6ebagj_3wX1hqa6HkXZXaXeQ3dW5Vysf4jZbENbHT5A83aeTZDK99FqKUfq8hoE5H9ciIfovrds8bhhxUdoy5SP0e1jf3f_BP3s4u6mxRz7-DA8FeZcTCaO_5vvkkFRTgtZuGhsDLteyEqvMbA0jBF-a9ymcmKPMAFdsJiIAsxcXDQVVy7FO6yvgqHqbhsX9biyWGAp1sYlkGJQ1hoUhQ9swXVpoB10evjx64ejwJeKCBTs8zKIrOBa6ESGaSpCzYRkkkXKKsOt0kYQTWUGxqFVDoBQR4bFsWLKigzsRdDQ9CkalFVpniNMiZYaLCMhrY5JGglQ7jHPQmWZ4BkLh2jUMkmuPI66K-cxy2t_iie524LcbUH9hA_R267DvIEQuZn0veO6jsxhf9cPqsUk96IkJxkoS-buiy2JhZIclJbRcRpbpRLtXvLG8WzuJBQMTAmfaAHTc1hf-RgsQvCqWQaUez1KkCyq17zbcn3uJdtFnkWMJ2BjRkOEu1bX0QXrlaZaXeQppTxxF_ZD9Kw5It2EiPvEkHFoSXuHpzfjfktZTGvUcwK-QRqSIdpvj9nVoG5czv3uHP5t6V_8A-0uutsEkdAg5HtosFyszEuwTZfylZc3vwCDPY3f |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+haemagglutination-inhibiting+antibody+titres+and+clinical+protection+against+influenza%3A+development+and+application+of+a+bayesian+random-effects+model&rft.jtitle=BMC+medical+research+methodology&rft.au=Coudeville%2C+Laurent&rft.au=Bailleux%2C+Fabrice&rft.au=Riche%2C+Benjamin&rft.au=Megas%2C+Fran%C3%A7oise&rft.date=2010-03-08&rft.eissn=1471-2288&rft.volume=10&rft.spage=18&rft_id=info:doi/10.1186%2F1471-2288-10-18&rft_id=info%3Apmid%2F20210985&rft.externalDocID=20210985 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2288&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2288&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2288&client=summon |